Advanced Oncotherapy – CEO, CFO & Non-Exec director purchase shares in the company

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Sanjeev Pandya, Chief Executive Officer, and Nicolas Serandour, Chief Financial Officer, informed the Company on 5 June 2015 that they individually purchased 220,000 ordinary shares of 1 penny each in the Company at 9 pence per Ordinary Share on that day.

In addition, the Company was informed on 5 June 2015 that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, purchased 1,500,000 Ordinary Shares at 9.81 pence per Ordinary Share on 3 June 2015.

Following these transactions Sanjeev Pandya now holds 590,400 Ordinary Shares representing 0.044% of the issued share capital of the Company, Nicolas Serandour now holds 220,000 Ordinary Shares representing 0.016%. Michael Bradfield now has a total beneficial interest in 122,018,510 Ordinary Shares representing 8.941%.